Atıf Formatları
The Role Adjuvant Chemotherapy in Resected Stage 1 NSCLC with High Risk Factors: A Turkish Oncology Group Study
  • IEEE
  • ACM
  • APA
  • Chicago
  • MLA
  • Harvard
  • BibTeX

Y. Eralp Et Al. , "The Role Adjuvant Chemotherapy in Resected Stage 1 NSCLC with High Risk Factors: A Turkish Oncology Group Study," JOURNAL OF THORACIC ONCOLOGY , no.10, 2019

Eralp, Y. Et Al. 2019. The Role Adjuvant Chemotherapy in Resected Stage 1 NSCLC with High Risk Factors: A Turkish Oncology Group Study. JOURNAL OF THORACIC ONCOLOGY , no.10 .

Eralp, Y., AK, N., Yilmazbayhan, D., ÖZKAN, B., FERHATOĞLU, F., DEMİRKAZIK, A., ... SAK, S.(2019). The Role Adjuvant Chemotherapy in Resected Stage 1 NSCLC with High Risk Factors: A Turkish Oncology Group Study. JOURNAL OF THORACIC ONCOLOGY , no.10.

Eralp, YEŞİM Et Al. "The Role Adjuvant Chemotherapy in Resected Stage 1 NSCLC with High Risk Factors: A Turkish Oncology Group Study," JOURNAL OF THORACIC ONCOLOGY , no.10, 2019

Eralp, YEŞİM Et Al. "The Role Adjuvant Chemotherapy in Resected Stage 1 NSCLC with High Risk Factors: A Turkish Oncology Group Study." JOURNAL OF THORACIC ONCOLOGY , no.10, 2019

Eralp, Y. Et Al. (2019) . "The Role Adjuvant Chemotherapy in Resected Stage 1 NSCLC with High Risk Factors: A Turkish Oncology Group Study." JOURNAL OF THORACIC ONCOLOGY , no.10.

@article{article, author={YEŞİM ERALP Et Al. }, title={The Role Adjuvant Chemotherapy in Resected Stage 1 NSCLC with High Risk Factors: A Turkish Oncology Group Study}, journal={JOURNAL OF THORACIC ONCOLOGY}, year=2019}